cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate · Medicine question

Which three adverse reactions were most frequently reported in clinical studies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead?

iatroX medicinesPublished 8 November 2026

The answer

Answer

The most frequently reported adverse reactions in clinical studies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead through 144 weeks were nausea (11%), diarrhoea (7%) and headache (6%).

Sources for this answer

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead 150mg/150mg/200mg/10mg film coated tabletsGilead Sciences Ltd · emc · SmPC §4.8 Undesirable effects · Version 37Document updated 22 October 2025

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate